Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2022-08-28 Capital/Financing Update
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - TLX 6 pages 28.1KB
Capital/Financing Update Classification · 95% confidence The document is an application for quotation of securities on the ASX by Telix Pharmaceuticals Limited. It details the number and type of securities to be quoted, issue dates, and compliance with listing rules. There is no financial performance data, earnings information, or management discussion. The document is a formal announcement related to capital markets activity, specifically the quotation of new securities. This fits the definition of a Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes.
2022-08-28 English
Appendix 4D - Results for announcement to the market 1
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4D' and is a 'Report for the half-year ended 30 June 2022,' which indicates it is a financial report covering a period shorter than a full fiscal year. It includes financial data such as revenue, loss after income tax, and net tangible asset backing for the half-year period. It references an Interim financial report and an auditor's review, which aligns with the characteristics of an Interim / Quarterly Report. The document length is 1811 characters, which is short but contains substantive financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-17 English
2022 Interim Report 39 pages 4.4MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Telix Pharmaceuticals Limited Interim Report 2022' and contains detailed sections such as Company directory, Directors' report, Auditor's independence declaration, and Financial report. It covers the half-year ended 30 June 2022, indicating it is a comprehensive financial report for a period shorter than a full fiscal year. The content includes financial results, operational review, strategy, risk management, and ESG information. The length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-17 English
1H 2022 - Results Presentation 33 pages 5.0MB
Interim / Quarterly Report Classification · 95% confidence The document is a detailed presentation from Telix Pharmaceuticals Limited covering multiple topics including 1H 2022 milestones, commercial updates, financial results overview, clinical programs update, pipeline expansion highlights, and outlook. It contains financial metrics such as revenue, cash balance, R&D investment, and loss after tax for the half-year period ending 1H 2022. The presence of detailed financial data and analysis for a half-year period indicates this is a comprehensive interim or quarterly report rather than a brief announcement or presentation. The document is not a transcript of a call, nor is it a proxy, audit, or governance report. It is not a short announcement or a certification letter. The content aligns with the definition of an Interim / Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year (half-year). H1 2022
2022-08-17 English
Ceasing to be a substantial holder 23 pages 459.2KB
Regulatory Filings
2022-08-17 English
Grand Pharmaceutical Group's investment in Telix 4 pages 431.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX release and a voluntary announcement by Grand Pharmaceutical Group regarding its strategic investment in Telix Pharmaceuticals. It discusses a partial divestment of shares, the nature of the investment, and the ongoing partnership. There are no financial statements, detailed financial performance data, or comprehensive report content. The document is an announcement about a capital transaction (partial sale of shares) and investment update rather than a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 8691 characters, which is sufficient for a detailed announcement but does not contain financial statements or management discussion typical of reports like 10-K or IR. Hence, the classification is CAP with high confidence.
2022-08-14 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.